Adrenal Cortical Carcinoma Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Adrenal Cortical Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI)48 enrolled44 locationsNCT06900595
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 2

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Adrenal Cortical CarcinomaLocally Advanced Adrenal Cortex CarcinomaStage III Adrenal Cortex Carcinoma+2 more
Emory University21 enrolled2 locationsNCT06006013
Recruiting

Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma

Adrenal Cortical Carcinoma
University Hospital, Strasbourg, France60 enrolled1 locationNCT07335679
Recruiting
Phase 2

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Adrenal Cortical Carcinoma
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia31 enrolled1 locationNCT07085572
Recruiting
Phase 2

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Adrenal Cortical CancerAdrenal Cortical CarcinomaAdrenal Cancer
West China Hospital28 enrolled1 locationNCT06831175